A recent study suggests that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a leading health publication demonstrates that while overweight people often shed a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments must be aware of the danger of fast rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
Such speed of regain implies a return to original weight in about 18 months.
Comparing Therapies
The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
Scientists note that individuals who lose weight through lifestyle changes alone generally have a less rapid weight regain—around 100 grams monthly—after stopping.
The Reason for the Quick Regain
Experts propose the mechanism of the jabs accounts for the amplified regain.
The injections copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making overeating much more probable."
A Chronic Issue?
Medical guidelines advise the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians say that, given the likelihood of weight regain, the therapy should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who say that the findings "emphasize the persistent character of excess weight," comparing it to managing diseases like hypertension.
Patient Accounts
Users who have discontinued the medication describe a powerful return of appetite.
"I experienced a switch activating and you become starving," said one woman.
This challenge is exacerbated if individuals have not adopted permanent dietary or behavioural modifications during therapy.
Significant Adoption
Survey data show that millions of people in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while the jabs are potent tools for weight loss, they are not a permanent cure and maintained weight loss likely depends on integrated lifestyle support.
